ShawnL.SearleMD

Family Medicine • Salt Lake City, UT

Addiction Medicine

Principal Investigator

Join to view full profile

Dr. Searle is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Searle's full profile

Already have an account?

Office
3838 S 700 E
Suite 202
Salt Lake City, UT 84106
Phone+1 801-269-8200
Is this information wrong?

Education & Training

University of Arizona College of Medicine-PhoenixResidency, Family Medicine, 1996 - 1999
The University of Texas Health Science Center at San AntonioClass of 1996

Certifications & Licensure

UT State Medical License 2013 - 2026
AZ State Medical License 1997 - 2018
WA State Medical License 2011 - 2014
American Board of Family Medicine Family Medicine

Clinical Trials

Safety Study of Topical Human FGF-1 for Wound Healing Start of enrollment: 2012 Nov 01
Unknown status
Phase 1
Omnitram Pharmacokinetic Study In Healthy Volunteers Start of enrollment: 2014 Aug 01
Completed
Phase 1
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia Start of enrollment: 2016 Mar 01
Completed
Phase 1
Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers Start of enrollment: 2017 Oct 31
Completed
Phase 1
Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users Start of enrollment: 2015 Jun 23
Completed
Phase 1
Absolute Oral Bioavailability of Remimazolam Start of enrollment: 2015 Nov 03
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

4 citations
Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.
Marja K Puurunen, Jerry Vockley, Shawn L Searle, Stephanie J Sacharow, John A Phillips 3rd, William S Denney, Benjamin D Goodlett, David A Wagner, Larry Blankstein, Ma...> ;Nature Metabolism. 2022 Sep 1
57 citations
Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.
Marja K. Puurunen, Jerry Vockley, Shawn Searle, Stephanie Sacharow, John A. Phillips, William S. Denney, Benjamin D. Goodlett, David A. Wagner, Larry Blankstein, Mary ...> ;Nature Metabolism. 2021 Jul 22
6 citations
Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-...
John A. Zebala, Shawn L. Searle, Lynn R. Webster, Matthew S. Johnson, Aaron D. Schuler, Dean Y. Maeda, Stuart J. Kahn> ;The Journal of Pain. 2019 Apr 18
4 citations
Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid...
Xiaofei Zhou, Sandeepraj Pusalkar, Swapan Chowdhury, Shawn Searle, Yuexian Li, Claudio Dansky Ullmann, Karthik Venkatakrishnan> ;Investigational New Drugs. 2019 Aug 1
18 citations
Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers a...
Jason M. Gow, Wayne Tsuji, Gary J. Williams, Daniel T. Mytych, David Sciberras, Shawn L. Searle, Tim Mant, John P. Gibbs> ;Arthritis Research & Therapy. 2015 Oct 8
Join now to see all

ShawnL.SearleMD

Dr. Searle is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.